Androgen deprivation therapy associated with increased risk for fatal heart attack
the ONA take:
Androgen deprivation therapy (ADT) and radiation therapy (RT) prolong survival in men with unfavorable-risk prostate cancer; however, evidence suggests that ADT is associated with nonfatal cardiovascular events.
Specifically, long-term follow-up of a randomized clinical trial that compared ADT and RT with RT alone showed that men with significant comorbidity, most commonly prior heart attack, who received ADT died earlier. These findings are published in a research letter in the Journal of the American Medical Association.
In this study, overall survival and death due to prostate cancer, fatal heart attack, and all other causes were analyzed. The study included 206 men with unfavorable-risk prostate cancer who were randomized to receive RT alone or RT and 6 months of ADT. The men were also categorized into subgroups based on prior comorbidity, including prior heart attack.
The findings demonstrate that prior heart attack is associated with an increased risk of fatal heart in men who receive ADT for unfavorable-risk prostate cancer.
Evidence suggests that androgen deprivation therapy is associated with nonfatal cardiovascular events.
Sign Up for Free e-newsletters
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer
- Better Postoperative Outcomes With RAMIE for Esophageal Cancer
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|